Abstract OT1-04-02: NRG oncology/RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain met from HER2-positive breast cancer — A collaborative study of RTOG & KROG (NCT01622868)

TY - JOUR

T1 - Abstract OT1-04-02: NRG oncology/RTOG 1119: Phase II randomized study of whole brain radiotherapy with concurrent lapatinib in patients with brain met from HER2-positive breast cancer — A collaborative study of RTOG & KROG (NCT01622868)

AU - White, null

AU - Moughan, J

AU - Kim, Ia

AU - Peereboom, Dm

AU - De Los Santos, Jf

AU - Sperduto, Pw

AU - Mehta, Mp

N1 - Abstracts: 2016 San Antonio Breast Cancer Symposium; December 6-10, 2016; San Antonio, Texas Background: The addition of trastuzumab to cytotoxic chemotherapy has improved outcomes for patients (pts) with HER2+ breast cancer. Increased survival coupled with limited blood-brain barrier (BBB) penetration of trastuzumab may contribute to the increased incidence of brain metastases (mets) in these pts.

PY - 2017/2/15

Y1 - 2017/2/15

UR - http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS16-OT1-04-02

U2 - 10.1158/1538-7445.SABCS16-OT1-04-02

DO - 10.1158/1538-7445.SABCS16-OT1-04-02

M3 - Article

VL - 77

JO - Cancer research

JF - Cancer research

ER -